Q-omics provides the consensus-scored HOXD-AS2 profile across patient tissues and cancer cell-line models. HOXD-AS2 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in LGG. Among the 18 cancer types available for tumor–normal comparison, HOXD-AS2 is differentially expressed in 14, with the highest sampling consensus in HNSC. Additionally, HOXD-AS2 RNA expression shows 13,152 significant protein co-abundance associations, with the highest sampling consensus in PDAC. Together, these results highlight LGG, HNSC, and PDAC as cancer lineages where HOXD-AS2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for HOXD-AS2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes HOXD-AS2 survival associations across molecular data types. HOXD-AS2 RNA expression shows survival associations in the most cancer types (23). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible HOXD-AS2 RNA expression–survival associations across cancer types. High HOXD-AS2 expression shows unfavorable associations in LGG, CESC, STAD, LIHC and UVM, but favorable associations in CHOL. The LGG Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify LGG as the clearest survival context for HOXD-AS2 RNA expression.
This table summarizes HOXD-AS2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14. The strongest signals are observed in HNSC for RNA.
This table ranks reproducible tumor–normal expression differences for HOXD-AS2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. HOXD-AS2 shows lower tumor expression in UCEC and KICH and higher tumor expression in HNSC, KIRC, LIHC and LUSC. The HNSC box plot shows higher HOXD-AS2 RNA expression in tumor versus normal tissue (log2 FC = +0.947, t-test p < 0.001).
This table shows molecular features associated with HOXD-AS2 in patient tissues and cancer cell lines. In patient samples, HOXD-AS2 shows the broadest associations at the RNA and protein expression levels, with PDAC recurring as the lineage with the largest associated feature set.
